trending Market Intelligence /marketintelligence/en/news-insights/trending/w8lgcfE7ughRRplJKOdLLQ2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

US FDA approves Anacor's eczema ointment

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


US FDA approves Anacor's eczema ointment

The U.S. FDA approved Anacor Pharmaceuticals Inc.'s Eucrisa ointment to treat mild to moderate eczema in patients two years of age and older.

The safety and efficacy of the ointment were established in two placebo-controlled trials with participants from two years of age to 79 years of age, with mild to moderate atopic dermatitis.

Participants in the trial receiving Eucrisa achieved greater response with clear or almost clear skin after 28 days of treatment.